The artificial intelligence (AI) in biotechnology market size was valued at USD 3.28 billion in 2024 and is expected to reach USD 13.30 billion by 2032, growing at a CAGR of 19.13% over 2025-2032.
The artificial intelligence (AI) in biotechnology market has undergone rapid change in recent years, and it is projected to exhibit even higher growth soon, driven by innovative developments, investments in research and development, and growing demand.
In April 2025, Plex Research launched a collaboration with Ginkgo Bioworks, which uses AI to identify new disease mechanisms and pathways for increased precision in drug targeting.
Companies at the forefront of using artificial intelligence (AI) in Biotech, such as Ginkgo Bioworks, Insilico Medicine, and Isomorphic Labs, are all leading developments for drug discovery with AI, drastically reducing the timeline and cost to develop new drugs. The boom in public and private investments, including Nestlé’s deep-tech hub in Switzerland and M42’s collaboration with Juvenescence, is a sign of the AI in Biotechnology market growth. These include strategic partnerships (Illumina and NVIDIA’s AI-based genomics partnership) and the U.S. export control regulations, which indicate increasing international attention and regulatory control.
R&D spending hikes are also catalysts that fashion the global artificial intelligence (AI) in biotechnology market, for instance, the AI-driven biotech funding projects from DARPA. These forces are helping to fuel burgeoning demand for faster drug pipelines, personalized medicine, and biosecurity preparedness. The artificial intelligence (AI) in biotechnology market is gaining traction, and the market is expanding and generation of highly advanced AI-powered platforms for protein engineering and disease modeling, taking the market to which next level, favoring artificial intelligence (AI) in biotechnology market growth.
In May 2025, Isomorphic Labs raised USD 600 million for next-gen drug design models, showcasing the growing investment appeal of AI-driven biotech innovation.
Notable Collaborations and Their Strategic Outcomes:
|
Collaborating Entities |
Year & Objective |
AI Application |
Strategic Value |
|
Amgen & AI Startups |
2024 – Tumor vaccine development |
Immune profiling, antigen prediction |
Accelerated immunotherapy design |
|
XtalPi & CK Life Sciences |
2024 – Protein-based drug discovery |
Protein folding prediction |
Shortened early-stage development |
|
Exscientia & Sanofi |
2023 – Precision oncology pipeline |
Personalized drug design |
Enhanced targeting in oncology trials |
|
BenevolentAI & AstraZeneca |
2023 – Target discovery for kidney diseases |
AI-based pathway identification |
Broader pipeline expansion |
|
Tempus & Cleveland Clinic |
2024 – Real-time clinical data modeling |
AI-guided treatment recommendations |
Improved patient care and clinical outcomes |
Market Dynamics:
Drivers:
Accelerated R&D, Strategic Alliances, and Automation in Biotech Innovation Fuel the Market Forward
The artificial intelligence (AI) in biotechnology market is heavily influenced by increasing AI penetration across genomics, pharmaceuticals, and bioengineering. Pharmaceutical and biotech industry leaders are using AI to improve drug development time frames and lab operations. Cradle Bio, for instance, has applied generative AI to protein engineering, speeding up development processes by more than 40%. Meanwhile, the U.S. Department of Defense’s 2024 budget directed a large experiment for AI-fueled biotech efforts as part of the BioMADE initiative, suggesting robust institutional buy-in.
By early 2025, over 60% of early-stage biotech pipelines will leverage AI. Growing demand for precision medicine and automated solutions is driving strong partnerships, such as Bristol Myers Squibb’s USD 400 million drug discovery partnership with AI Proteins. Overall, these efforts collectively drive the artificial intelligence (AI) in biotechnology market growth, boosting the artificial intelligence (AI) in biotechnology market share across different applications. A growing number of AI-based biotech incubators and increasing venture capital investments for automation technologies fuel the growth of the global artificial intelligence (AI) in biotechnology market. The continued development of personalized medicine and artificial intelligence (AI) based biologics is playing a significant role in shaping the artificial intelligence (AI) in biotechnology market trends.
Restraints:
Data Fragmentation, IP Issues, and Regulatory Complexities Hinder Market Growth
Although innovative development is happening rapidly, there are key constraints to the artificial intelligence (AI) in biotechnology market that could prevent growth. Foremost among these are the hurdles of regulatory uncertainty and standardization of data. The absence of harmonized global frameworks for AI deployment in clinical research and synthetic biology presents challenges for compliance.
In late 2024, the U.S. placed export controls on advanced biotech equipment associated with AI, resulting in fears over limited international supply chains. These were policies that affected multiple AI in biotech companies working with global partnerships for scale solutions. Furthermore, a lack of common datasets and divided databases results in the low precision of AI, especially in the fields of genomics and proteomics.
Intellectual property (IP) disputes also slow innovation. AI-created molecules frequently do not have an obvious IP owner, creating challenges for commercialization. Approval of AI-based treatments is still a plodding process, despite pilot projects from the FDA and EMA. These factors act as market barriers to artificial intelligence (AI) in biotechnology entry. As such, issues associated with artificial intelligence (AI) in biotechnology market analysis and commercialization globally may challenge the artificial intelligence (AI) in biotechnology market companies. However, it is still a hard task to sustainable grow the market of artificial intelligence (AI) in biotechnology in the dynamic marketplace of the global artificial intelligence (AI) in biotechnology.
Segmentation Analysis:
By Component
The software segment dominated the artificial intelligence (AI) in biotechnology market, with a revenue share of 46% in 2024. This domination is mainly due to the increasing use of AI platforms in computational drug design, genomic analysis, and predictive models in biotechnology processes. Solutions including Schrödinger’s software and DeepMind’s AlphaFold have facilitated a high-throughput simulation and protein folding prediction that drastically improve the productivity of R&D. Additionally, cloud-based systems and AI-based technology are becoming integrated into laboratory informatics system technologies, allowing scalable analysis.
However, services became the fastest-growing segment as demand increased for AI consulting, customization, and deployment services. Biotech companies and research organizations are increasingly investing in AI solutions to technology providers, harvesting the benefits of focused solutions and increasing operational effectiveness and time-to-market.
By Application
In 2024, the drug discovery and development segment had the highest artificial intelligence (AI) in biotechnology share, with 42% and it was the dominant segment in 2024. This growth was driven by the fast application of AI algorithms in molecular target identification, compound screening, and lead optimization activities. Firms are employing AI to cut the costs of R&D, shrink discovery timelines, and raise the rate of success for drug candidates. These include the employment of generative AI for de novo drug design and AI-based machine learning to predict compound efficacy and toxicity.
On the other hand, in terms of artificial intelligence (AI) in biotechnology growth, the clinical trials and optimization segment was identified as the fastest segment due to the rising adoption of AI for patient screening, real-time monitoring of the trials, and designing protocols. Artificial intelligence’s power to compute huge volumes of health data and forecast trial results is streamlining and demystifying the process of clinical research.
Key Applications of AI in Biotechnology and Their Impact:
|
Application Area |
Description |
AI Contribution |
Key Benefits |
|
Drug Discovery & Development |
Screening, molecule design, target ID |
In silico simulations, target prediction, and compound modeling |
Reduces timelines & cost by up to 40% |
|
Precision Medicine |
Personalized treatment based on genetics |
Patient-specific modeling, treatment recommendation engines |
Improved efficacy and reduced adverse effects |
|
Diagnostics |
Disease identification using biological and imaging data |
AI-enabled imaging, biomarker detection |
Faster and more accurate diagnostics |
|
Agriculture |
Crop yield, disease detection, genomics |
Predictive models, soil & genome analytics |
Higher yield, better resistance |
|
Environmental & Forensics |
Bioremediation, genetic forensics |
Pattern recognition, bio-trace analysis |
Efficient environmental monitoring |
By End-User
Pharmaceutical companies dominated the market share of artificial intelligence (AI) in biotechnology in 2024, with a share of 38.3% of the market. It’s being driven largely by big pharma companies making significant investments in AI technologies to transform drug discovery pipelines, lower costs associated with clinical trials, and optimize precision medicine approaches. AI is also being used by companies to automate the process of target validation and to accelerate biomarker discovery. The trend is also supported by a recent spate of pharma deals with AI providers, such as the ones between Valo Health and Tempus.
Meanwhile, CROs and CDMOs were the fastest-growing type of end-user. Pharma is also now outsourcing more and more of its R&D, and they too are onboarding AI tools for preclinical and clinical services at a faster pace purely to tap into these insights and operational scale, as well as the deep technical expertise that AI implementations require.
Regional Analysis:
North America held artificial intelligence (AI) in biotechnology market share in 2024, owing to the presence of robust R&D facilities, a well-established healthcare system, and large investments by biotech and pharmaceutical companies.
The U.S. artificial intelligence (AI) in biotechnology market size was valued at USD 1.14 billion in 2024 and is expected to reach USD 4.24 billion by 2032, growing at a CAGR of 17.90% over 2025-2032. The U.S. held the highest share in the region owing to the high implementation of AI technology in drug development, the presence of major players (NVIDIA, Illumina, and Tempus) headquartered in the country, and significant investment by the government. More than 60% of AI biotech startups globally in 2024 were U.S.-based, indicating the country’s technology leadership and robust VC environment. Canada is quickly establishing a foothold, with AI hubs in Toronto and Montreal, and government programs including the Pan-Canadian AI Strategy. Among developing countries, Mexico has increasingly begun to adopt AI tools for health research, as academic and private partnerships have risen rapidly.
Artificial intelligence (AI) in biotechnology market in Europe was the second dominant and is projected to witness considerable growth, led by highly developed innovation-centric economies and robust regulatory support for the ethical use of AI in life sciences. Germany prevailed in the region due to its strong base in pharmaceutical manufacturing, substantial government contributions, and collaborations between academia and biotech companies. There are over 80 AI-biotech joint ventures in Germany nowadays. The U.K. is growing more quickly than any other country in the region, boosted by companies such as Exscientia and Benevolent AI, and government support through NHS-linked genomic and drug discovery programmes.
The Asia Pacific AI in biotechnology market is projected to register the highest CAGR in the coming years, primarily due to growing investments, favorable government initiatives, and the rapid digitalization of healthcare. China dominated the region, supported by an ambitious state-funded biotech expansion and AI development initiative in the context of “Healthy China 2030” and AI national strategies. In 2024, China filed over 300 biotech patents that referenced AI, which was the largest number of patents of any APAC country. It also has rapid growth in AI-wellness convergence and precision medicine, with national initiatives including BIRAC and iHub-Data. Japan is turning its tech-savvy ecosystem and aging population toward AI-powered diagnostics and therapeutics. Growing partnerships with Western biotech companies and uptake of AI platforms in genomics, imaging, and drug development are driving the region’s push, especially in Singapore and South Korea, which are regional AI-health innovation hubs.
Regional Influence in AI in Biotechnology Market (2024):
|
Influence Level |
Region & Country |
Key Strengths |
|---|---|---|
|
High |
United States |
Strongest global leader with highest AI-biotech integration, R&D funding, and startup density. |
|
High |
China |
Aggressive government-led AI and biotech investments; fastest-growing patent activity. |
|
Strong |
Germany |
Deep-rooted pharma industry with AI compliance and ethical integration. |
|
Strong |
India |
Emerging biotech hubs, AI research initiatives, and a strong talent pool. |
|
Strong |
Japan |
Advanced imaging diagnostics and AI-health tech innovation. |
|
Moderate |
Canada |
Government-backed AI frameworks and rising AI-biotech collaborations. |
|
Moderate |
South Korea |
National focus on biotech AI R&D and startup acceleration programs. |
|
Low |
Brazil |
Growing AI use in diagnostics and genomic medicine: an emerging ecosystem. |
|
Low |
Saudi Arabia |
Vision 2030 is driving AI in biotech healthcare transformation. |
|
Emerging |
South Africa |
Nascent development in AI-biotech, mainly through academic initiatives. |
Key Players:
Leading artificial intelligence (AI) in biotechnology companies in the market include Tempus, NVIDIA, Insilico Medicine, Schrödinger, Deep Genomics, SOPHiA GENETICS, Exscientia, Recursion Pharmaceuticals, Illumina, and BenevolentAI.
Recent Developments:
In May 2025, Insilico Medicine reported via Nature Communications the AI-enabled design of ISM5939, a next-gen ENPP1 inhibitor tackling immune checkpoint resistance, demonstrating AI’s growing efficacy in fast-tracking drug candidate development.
In January 2025, Illumina integrated its DRAGEN multi-omics analysis platform with NVIDIA’s BioNeMo and MONAI AI frameworks to accelerate large-scale genomic data processing for drug discovery and clinical research.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 3.28 billion |
| Market Size by 2032 | USD 13.30 billion |
| CAGR | CAGR of19.13% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Component (Software, Hardware, and Services) • By Application (Drug Discovery & Development, Clinical Trials & Optimization, Medical Imaging, Diagnostics, and Others) • By End User (Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes, Healthcare Providers, CRO & CDMO, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Tempus, NVIDIA, Insilico Medicine, Schrödinger, Deep Genomics, SOPHiA GENETICS, Exscientia, Recursion Pharmaceuticals, Illumina, and BenevolentAI. |
Ans: The artificial intelligence (AI) in biotechnology market was valued at USD 3.28 billion in 2024.
Ans: Key trends include the rising use of AI in drug discovery and genomics, integration of machine learning in clinical trials, increasing collaborations between AI firms and biotech companies, and the growing demand for precision medicine.
Ans: Major players include IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Deep Genomics, PathAI, BenevolentAI, and Exscientia, among others.
Ans: The market is projected to reach USD 13.30 billion by 2032, growing at a CAGR of 19.13% from 2025 to 2032.
Ans: Key challenges include data privacy concerns, lack of standardized AI frameworks, high implementation costs, and limited availability of high-quality, annotated biological data.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 AI Adoption Rate in Biotechnology Companies, by Region (2021–2024)
5.2 AI-Driven Drug Discovery Projects, by Application Area (2024)
5.3 R&D Efficiency Gains Attributed to AI (Time & Cost Savings), Global, 2024
5.4 Venture Capital and Government Funding in AI-Biotech Startups, by Region (2021–2024)
5.5 AI Patent Filings and Publications in Biotechnology, by Country (2020–2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Artificial Intelligence (AI) in Biotechnology Market Segmentation by Component
7.1 Chapter Overview
7.2 Software
7.2.1 Software Market Trends Analysis (2021-2032)
7.2.2 Software Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Hardware
7.3.1 Hardware Market Trends Analysis (2021-2032)
7.3.2 Hardware Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Services
7.4.1 Services Market Trends Analysis (2021-2032)
7.4.2 Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Artificial Intelligence (AI) in Biotechnology Market Segmentation By Application
8.1 Chapter Overview
8.2 Drug Discovery & Development
8.2.1 Drug Discovery & Development Market Trend Analysis (2021-2032)
8.2.2 Drug Discovery & Development Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Clinical Trials & Optimization
8.3.1 Clinical Trials & Optimization Market Trends Analysis (2021-2032)
8.3.2 Clinical Trials & Optimization Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Medical Imaging
8.4.1 Medical Imaging Market Trends Analysis (2021-2032)
8.4.2 Medical Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Diagnostics
8.5.1 Diagnostics Market Trends Analysis (2021-2032)
8.5.2 Diagnostics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Others
8.6.1 Others Market Trends Analysis (2021-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Artificial Intelligence (AI) in Biotechnology Market Segmentation By End User
9.1 Chapter Overview
9.2 Pharmaceutical Companies
9.2.1 Pharmaceutical Companies Market Trends Analysis (2021-2032)
9.2.2 Pharmaceutical Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Biotechnology Companies
9.3.1 Biotechnology Companies Market Trends Analysis (2021-2032)
9.3.2 Biotechnology Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Academic & Research Institutes
9.4.1 Academic & Research Institutes Market Trends Analysis (2021-2032)
9.4.2 Academic & Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Healthcare Providers
9.5.1 Healthcare Providers Market Trends Analysis (2021-2032)
9.5.2 Healthcare Providers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.6 CRO & CDMO
9.6.1 CRO & CDMO Market Trends Analysis (2021-2032)
9.6.2 CRO & CDMO Market Size Estimates and Forecasts to 2032 (USD Billion)
9.7 Others
9.7.1 Others Market Trends Analysis (2021-2032)
9.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.2.4 North America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.5 North America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.2.6.2 USA Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.6.3 USA Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.2.7.2 Canada Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.7.3 Canada Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.2.8.2 Mexico Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.8.3 Mexico Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.4 Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.5 Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.1.6.2 Germany Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.1.6.3 Germany Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.7.2 France Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.7.3 France Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.8.2 UK Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.8.3 UK Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.9.2 Italy Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.9.3 Italy Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.10.2 Spain Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.10.3 Spain Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.12.3 Poland Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.12.3 Poland Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.13.2 Turkey Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.13.3 Turkey Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.6.2 China Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.6.3 China Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.7.2 India Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.7.3 India Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.8.2 Japan Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.8.3 Japan Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.9.2 South Korea Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.9.3 South Korea Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.10.2 Singapore Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.10.3 Singapore Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.11.2 Australia Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.11.3 Australia Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.5.6.2 UAE Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.6.3 UAE Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.5.8.2 Qatar Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.8.3 Qatar Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.5.9 2 South Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
10.5.9 3 South Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.6.4 Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.5 Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.6.6.2 Brazil Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.6.3 Brazil Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.6.7.2 Argentina Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.7.3 Argentina Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, by Component (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Artificial Intelligence (AI) in Biotechnology Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
12. Company Profiles
12.1 Tempus
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 NVIDIA
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Insilico Medicine
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Schrödinger
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Deep Genomics
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 SOPHiA GENETICS
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Exscientia
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Recursion Pharmaceuticals
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Illumina
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 BenevolentAI
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Component
Software
Hardware
Services
By Application
Drug Discovery & Development
Clinical Trials & Optimization
Medical Imaging
Diagnostics
Others
By End User
Pharmaceutical Companies
Biotechnology Companies
Academic & Research Institutes
Healthcare Providers
CRO & CDMO
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players